Literature DB >> 6831651

Role of calcium antagonists in the treatment of essential hypertension.

W Klein, D Brandt, K Vrecko, M Härringer.   

Abstract

The calcium antagonists, diltiazem and nifedipine, are effective in mild-to-moderate chronic essential hypertension. The overall responder rate is 80%. Diastolic blood pressure is lowered by 10-15% at rest and during exercise. Systolic blood pressure is reduced only at rest. Heart rate may be unchanged by nifedipine and lowered by diltiazem. Both drugs lead to a decrease of peripheral resistance by 15-20% at rest and 30% during work. As a consequence of afterload reduction, cardiac output, stroke index, and stroke work index increased by 17, 21, and 7% with nifedipine and 34, 26, and 20% with diltiazem. During exercise, these changes are even more pronounced. However, pulmonary artery pressure and pulmonary vascular resistance are reduced only by nifedipine, not by diltiazem. Presumably due to this combined preload and afterload reduction, nifedipine therapy is associated with a reflex activation of the sympathetic nervous system in all cases, with an increase in norepinephrine plasma concentration and, sometimes, tachycardia. Diltiazem, however, has the advantage of being a potent blood pressure-lowering agent, with afterload reduction and increased stroke index, with less pronounced catecholamine increase, and without tachycardia. Side effects with this drug are rare, and long-term therapy is well tolerated.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6831651

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  11 in total

1.  Co-dergocrine mesylate inhibits the increase in plasma catecholamines caused by nifedipine in essential hypertension.

Authors:  R Kirsten; K Nelson; G Weidinger; D Welzel
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

Review 2.  Nifedipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, in ischaemic heart disease, hypertension and related cardiovascular disorders.

Authors:  E M Sorkin; S P Clissold; R N Brogden
Journal:  Drugs       Date:  1985-09       Impact factor: 9.546

3.  Assessment of left ventricular function after sublingual administration of nifedipine in patients with moderate to severe hypertension.

Authors:  H Hayashi; M Iwase; T Aoki; M Yokota
Journal:  Cardiovasc Drugs Ther       Date:  1990-08       Impact factor: 3.727

Review 4.  Calcium channel antagonism and beta blockade in combination--a therapeutic alternative in cardiovascular disorders. A review.

Authors:  J N Lessem; B N Singh
Journal:  Cardiovasc Drugs Ther       Date:  1989-06       Impact factor: 3.727

Review 5.  Diltiazem.

Authors:  B A Britt
Journal:  Can Anaesth Soc J       Date:  1985-01

Review 6.  Diltiazem. A review of its pharmacological properties and therapeutic efficacy.

Authors:  M Chaffman; R N Brogden
Journal:  Drugs       Date:  1985-05       Impact factor: 9.546

Review 7.  Endocrine physiology of electrolyte metabolism.

Authors:  K G Dawson
Journal:  Drugs       Date:  1984-10       Impact factor: 9.546

8.  Hemodynamic effects of Ro 23-6152 in patients with essential hypertension.

Authors:  H B Folkers; J C van Zwienen; P Boer; C H Kleinbloesem; G G Geyskes
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

Review 9.  Calcium channel antagonists. Part III: Use and comparative efficacy in hypertension and supraventricular arrhythmias. Minor indications.

Authors:  L H Opie
Journal:  Cardiovasc Drugs Ther       Date:  1988-03       Impact factor: 3.727

10.  Efficacy of the calcium antagonist isradipine in angina pectoris.

Authors:  J O Parker; M Enjalbert; V Bernstein
Journal:  Cardiovasc Drugs Ther       Date:  1988-03       Impact factor: 3.727

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.